MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-07-2024
Alimera Sciences EPS Ratio 2011-2026 | ALIM
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.84 | -2.59 | -0.66 | -1.04 | -2.19 | 0.25 | -0.33 | -0.63 | -0.69 | -0.91 | -1.62 | -0.63 | -0.72 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.25 | -2.59 | -0.969 |
Quarterly EPS Ratio Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -0.12 | - | -1.32 | -0.71 | - | -0.75 | -0.45 | -0.85 | - | -0.6 | 1.03 | -0.63 | - | -0.12 | -0.51 | -0.24 | - | -0.04 | -1.06 | -0.59 | - | 0.4 | -0.06 | -0.11 | -0.1 | -0.08 | -0.04 | -0.1 | -0.09 | -0.16 | -0.15 | -0.25 | -0.24 | -0.03 | -0.19 | -0.22 | -0.23 | -0.17 | 0.03 | -0.58 | - | -0.04 | -0.67 | -0.44 | - | -0.17 | -0.15 | -0.14 | - | -0.21 | -0.17 | -0.15 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 | -1.32 | -0.262 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
-4.74 | $ 18.02 | -2.12 % | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 3.11 | -0.96 % | $ 43.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 5.39 | 0.75 % | $ 1.97 B | Canada |
 |
Harrow Health
HROW
|
-0.14 | $ 37.29 | 1.52 % | $ 1.37 B | USA |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.09 | 4.81 % | $ 117 M | Canada |
 |
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-0.8 | $ 4.24 | 3.67 % | $ 273 M | USA |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 8.45 | 0.72 % | $ 433 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
-0.51 | $ 1.44 | 3.6 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.29 | -4.18 % | $ 302 M | USA |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 23.82 | 2.45 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | $ 1.38 | 1.47 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-1.45 | $ 7.61 | 8.56 % | $ 300 M | USA |
 |
SCYNEXIS
SCYX
|
-0.17 | $ 0.99 | -0.4 % | $ 49.4 M | USA |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-1.99 | $ 8.1 | 1.0 % | $ 709 M | USA |
 |
Tilray
TLRY
|
-2.35 | $ 6.72 | -0.44 % | $ 4.15 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 2.41 | 5.24 % | $ 2.99 M | USA |
 |
Veru
VERU
|
-0.28 | $ 2.43 | -4.71 % | $ 328 M | USA |
 |
Viatris
VTRS
|
0.05 | $ 13.61 | 0.29 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 0.65 | -6.59 % | $ 2.8 M | USA |
 |
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-0.15 | $ 0.93 | -0.98 % | $ 33.5 M | USA |
 |
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.74 | $ 0.66 | 5.66 % | $ 2.83 M |  China |
 |
TherapeuticsMD
TXMD
|
-0.05 | $ 2.05 | - | $ 23.7 M | USA |